[Clinical evaluation of a new carbapenem antibiotic, biapenem (L-627), in the pediatric field].

Abstract

Biapenem (L-627) was evaluated for its safety and efficacy in 27 children with various bacterial infections. L-627 was effective in cases with osteomyelitis due to Staphylococcus aureus, pneumonia and purulent meningitis due to penicillin-resistant Streptococcus pneumoniae, and urinary tract infections due to Enterococcus faecalis, Escherichia coli, or Pseudomonas aeruginosa. However, L-627 failed to produce good responses in 2 of 7 cases of Haemophilus influenzae infections. Pharmacokinetic parameters of 30-minutes infusion of 12 mg/kg were as follows: Cmax 29-46 micrograms/ml, T 1/2 0.68-0.94 hr. Adverse reactions were minimal. These data suggest that L-627 is safe in children, and is valuable especially for treatment of infections in immunocompromised hosts and infections due to multiply resistant bacteria.

• Authors: H Meguro, R Fujii, I Terashima, N Ishikawa, H Kuroki, H Niimi, A Nakamura, H Ohshima, T Kurosaki, T Toba
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 47 Issue 7 Pg. 903-13 (Jul 1994) ISSN: 0368-2781 [Print] Japan
• PMID: 7933525 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Thienamycins
• biapenem

Topics

• Adolescent
• Bacterial Infections (drug therapy, metabolism)
• Child
• Child, Preschool
• Female
• Humans
• Infant
• Male
• Meningitis, Bacterial (drug therapy, metabolism)
• Osteomyelitis (drug therapy, metabolism)
• Thienamycins (pharmacokinetics, therapeutic use)